Pfizer (NYSE:PFE) Trading Up 1.6% – Here’s Why

Pfizer Inc. (NYSE:PFE)’s stock price shot up 1.6% during trading on Tuesday . The company traded as high as $27.40 and last traded at $27.2950. 34,599,379 shares changed hands during mid-day trading, a decline of 18% from the average session volume of 42,104,363 shares. The stock had previously closed at $26.87.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Lyme vaccine filing advances in Europe: The European Medicines Agency validated Pfizer and Valneva’s marketing application for their Lyme disease vaccine candidate, confirming that the submission is ready for full regulatory review. The filing follows late-stage results showing 73% efficacy and encouraging safety data, improving the prospects for a future product launch and potential royalty income. Pfizer Gets EMA Lyme Vaccine Filing Validation
• Positive Sentiment: Pipeline diversification continues: Pfizer completed a Phase 1 study of experimental obesity drug PF-08653944. The program remains at an early stage, so it is not an immediate earnings driver, but progress could help investors looking for growth areas beyond Pfizer’s mature COVID-19 portfolio. Pfizer Advances Early Obesity Drug PF-08653944
• Positive Sentiment: Healthcare-sector support: The broader healthcare sector was higher during Tuesday’s session, providing a favorable trading backdrop for Pfizer and other defensive pharmaceutical stocks. Healthcare Stocks Rise Tuesday Afternoon
• Neutral Sentiment: Valuation and income appeal: Commentary continues to characterize Pfizer as inexpensive and supported by a sizable dividend, with pharmaceuticals offering relatively defensive demand. These benefits may attract income-oriented investors, although they depend on stable cash flow and successful replacement of aging products. Warren Buffett and Greg Abel Keep Overlooking This Stock
• Negative Sentiment: Patent-cliff risk remains: Analysts note that Pfizer’s low valuation reflects looming patent expirations and the resulting threat to revenue and earnings. Investors will therefore need to weigh the Lyme vaccine and obesity programs against the timing and scale of replacement products. Pfizer Still Cheap Valuation Meets a Looming Patent Cliff

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Bank of America dropped their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Wolfe Research reiterated an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. Citigroup raised their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. cut their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock has a market cap of $155.57 billion, a P/E ratio of 35.91 and a beta of 0.34. The business’s 50-day moving average price is $25.15 and its 200-day moving average price is $26.20.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. Pfizer’s payout ratio is 226.32%.

Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at $26,000. Keb Asset Management LLC purchased a new stake in Pfizer in the 2nd quarter worth $26,000. HFM Investment Advisors LLC raised its holdings in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Evolution Wealth Management Inc. lifted its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares in the last quarter. Finally, Abound Financial LLC bought a new position in shares of Pfizer in the fourth quarter worth about $31,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.